A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors

Summary

This is an open-label, dose-escalation study of the study drug YH001 . The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 in subjects with advanced solid tumors.

Timeline

Start

2021-01-26

Primary completion

2022-10-08

Completion

2022-10-08

Drugs

Indications